The Round 3 program will run from 2019-2021. The investment decision making process is scheduled to begin in 2019, with project start-up in late 2019, and capability activities transitioning into core Queensland Health before the Queensland Genomics program concludes in 2021.
Early work has begun on the Round 3 investment, and it is planned to include elements in pharmacogenomics, along with stronger engagement with the primary health care system and allied health, as well as strengthen national and international collaborations.
Further details about Round 3 will be released in early 2019.
To stay up to date on Queensland Genomics activities and future funding opportunities, sign up for our eNewsletter.